July 9, 2021 7:33am
We should be enjoying this season of grilling even under the clouds of rain beneath the patio umbrella; instead, I’m “bitchin” about the cell and gene therapy sector and markets
Pre-open indications: 1 Maintain SELL: BSTG
My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
Dow futures are UP +0.64% (+221 points), S&P futures are UP +0.42% (+18 point) and NASDAQ futures are DOWN -0.01% (-2 points)
Stock futures were mostly higher in early morning trading Friday
European stocks traded higher,
Asia-Pacific stocks fell as Covid worries resurfaced in the region.
Henry’omics:
All three major averages are on track to close lower for the week …
Thursday’s losses have been attributed to the spread of the highly infectious delta Covid variant which has caused a ban of Olympic spectators at Tokyo’s summer games as Japan declared a state of emergency to curb the spread of coronavirus as Pfizer (PFE) weighs-in about a third defense booster shot.
I belief fear of everything has caused sentiment without news or data to be the real culprit for the sector’s crash but, it did see a ray daylight (i.e., a barely positive close) after Wednesday, Tuesday and last Friday’s Advance/Decline (A/D) line crashes.
There is just NO strength or resolve to weather these negative session closes.
Thursday’s evening’s recap: “past downslide is an upside for some cell and gene therapy equities. Sensing some cracks and leaks in “our” universe” … https://www.regmedinvestors.com/articles/11990
- The Nasdaq closed DOWN -105.28 points (-0.72%);
- The IBB closed up +0.20% and XBI closed up +0.48%
- Sector volume was LOW with 2 of the 17-upside having higher than the 3-month average volume with LOW volume of 4 of 16-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was up +2.80 points or +17.28% at 19;
- Thursday’s percentage (%) of the 17-upside were +0.66% (MESO) to +18.11% (BSTG) while the 16-downside ranges from -0.05% (ALNY) to -6.21% (MDXG);
Q3/21: 2 positive and 3 negative close
Q2/21:
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) - Maintaining Sell – Could the share price stay up if it wasn’t “pumped”?
Biostage (BSTG) closed up +$0.23 to $1.50 with 210 shares traded after Wednesday’s -$0.23 to $1.27 with 15,903 shares traded, Tuesday’s +$0.15 to $1.50 with 5,702 shares traded and the previous Friday’s -$0.00 with 1,974 shares traded.
Question#1: WHAT role is DST Capital “playing” in these on-going “volume-pumping” pricing “moves” – to exercise the remaining outstanding warrants to add even more unregistered shares to the “outstanding”?
Question#2: WHO and WHAT has facilitated <” made it easy or easier to get where they are”> most of the issues with BSTG?
Question#3: Is protecting the share price the ONLY factor indicative of a “packed and inflated” pricing of the private placements that has jeopardized ANY sort of future financing?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
The morning’s indications: No overwatch today, just too perilous to prognosticate and I hate to mislead any investor!
The BOTTOM LINE: It takes courage to not being discouraged by this sector …
In my role as a research analyst and journalist is a balancing “act”, WHAT CHANGES; many times, I scratch my head over how to cover volatile cell and gene therapy equities – it’s the INDICATIONS that focus my “leanings”.
I also continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored.
My focus has always been “indication and warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
